DIATEC: median inpatient time in range was 77.6% versus 62.7%. CGM was part of diabetes-team-guided insulin titration, not a standalone sensor intervention. Read the PICO on Hormone Insight.

IoN supports omitting radioiodine in appropriately selected low-risk thyroid cancer. Non-inferiority is not a blanket recommendation for every patient after thyroidectomy. Read the PICO on Hormone Insight.

Infrequent zoledronate: 10-year radiographic vertebral fracture rates were 6.3% versus 11.1% with placebo. Selected early postmenopausal women, not a universal dosing rule. Read the PICO on Hormone Insight.

Baxdrostat and resistant hypertension. Explore the study design, endpoints and limitations. Read the PICO on Hormone Insight.

OASIS-3: elinzanetant reduced vasomotor symptoms at week 12. Treatment-related adverse events were more common than with placebo. Benefit and tolerability belong in the same discussion. Read the PICO on Hormone Insight.

TANDEM: obicetrapib plus ezetimibe lowered LDL at 84 days. The trial measured lipid efficacy, not cardiovascular event prevention. Read the result and its limits. Read the PICO on Hormone Insight.

foresiGHt: weekly lonapegsomatropin improved trunk fat versus placebo in adult GH deficiency. A body-composition result, not proof of cardiovascular benefit or superiority to daily GH. Read the PICO on Hormone Insight.

ORBIT: secukinumab did not demonstrate efficacy in Graves orbitopathy. Primary response at week 16: 0/14 versus 0/14 with placebo. Small trial; no basis for routine use. Read the PICO on Hormone Insight.

Denosumab and teriparatide: a bone-biopsy study. Explore the study design, endpoints and limitations. Read the PICO on Hormone Insight.

Prednisolone versus hydrocortisone: lower bone-turnover markers are not proof of fewer fractures. A small crossover trial, with important limits. Read the PICO on Hormone Insight.

SOUL: oral semaglutide vs placebo in 9,650 high-risk adults with T2D. MACE 12.0% vs 13.8%; HR 0.86 (95% CI 0.77-0.96), P=0.006. Kidney-outcome boundary matters. PMID 40162642.

If your thyroid eye disease went chronic and you were told nothing more could be done, that just changed. FDA approved Lumvoa (veligrotug) with actual trial data in chronic TED, not just active disease. 49% had diplopia fully resolve. #ThyroidEyeDisease #Endocrinology

A practical guide to Zucchini Recipes for Diabetes: Summer Meals Without Carb Guesswork: key questions, preparation, and when to involve your care team. livingdiabetes.com/zucchini-… #Diabetes #Health

He has been on the same small pill for nine years. He has come, today, to tell me that he does not believe in it. He points at the leaflet. He says it can cause everything. Doctor's Diary, Entry 7. hormoneinsight.com/diary/ #doctorsdiary

Pearl: aquatic exercise cut systolic AND diastolic BP in T2DM — buoyancy reduces joint loading up to 80%. Ideal with obesity or arthritis. #ExerciseMedicine 📖 hormoneinsight.com/can-aquat… 📱 iOS: apps.apple.com/us/app/hormon… Android: shorturl.at/FvKeT

It is the fellow's first day. She has brought two pens. The second pen, in case. A patient with eleven problems wants a comprehensive opinion. I ask him to pick one. Doctor's Diary, Entry 6. hormoneinsight.com/diary/ #doctorsdiary

LEADER (NEJM 2016): the first GLP-1 trial to cut cardiovascular death (−22%). The moment a diabetes drug became a cardiovascular drug. 📖 hormoneinsight.com/leader-li… 📱 iOS: apps.apple.com/us/app/hormon… Android: shorturl.at/FvKeT